|Applications||Control Manufacture, Diagnostic controls and calibrators, ELISA, Immunoassay, in vitro diagnostics, Sandwich ELISA|
|Disease Area||Cancer Markers|
|Function in Disease||
CEA was first identified in human colon carcinoma tissue extracts and is known to play a critical role as a ligand in cancer dissemination. Elevated serum CEA is found in 17∼47% of colorectal cancer patients.
CEA was originally thought to be a specific marker for colon cancer but levels may also be raised in gastric, pancreatic, lung, breast and medullary thyroid carcinomas, as well as some non-neoplastic conditions such as inflammation, pancreatitis, ulcerative colitis, cirrhosis, COPD, Crohn's disease, hypothyroidism and in smokers. For this reason, it is not useful as a general cancer screening tool, but can be useful in evaluating the response to cancer treatment, to monitor metastasis of colorectal cancer to the liver and to indicate recurrence.
Elevated CEA levels should return to normal after successful surgical removal of the tumour and can be used in follow up, especially of colorectal cancers. CEA elevation is known to be affected by multiple factors and it varies inversely with tumor grade; well-differentiated tumours secrete more CEA.
|Health and Safety||
For Research and Manufacturing only
|Presentation Matrix||Clear, colourless solution, single homogeneous batch, 0.2µm filtered, supplied frozen in 20.4nM sodium phosphate, 1.5mM potassium phosphate buffer containing 0.136M sodium chloride and 2.7mM potassium chloride, pH7.4.|
As a concentrated reagent diluted into a matrix to prepare calibrators for ELISA or other Immunoassays
In combination with other tumour markers to prepare a tumour marker control, usually at different levels
For the preparation of External Quality Assurance materials for intra-laboratory assay performance testing
|Shipping Recommendation||Dry Ice|
|Source||Human Cell Line|
|Storage||Store below -15°C|
|Tested Applications||Sandwich ELISA|